8-K 1 odyssey_8k.htm FORM 8-K







Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): August 4, 2021



(Exact name of small business issuer as specified in its charter)



Nevada 000-56196 47-1022125

(State or other jurisdiction of incorporation)

(Commission File Number) (IRS Employer ID No.)



2372 Morse Ave., Irvine, CA 92614
(Address of principal executive offices) (Zip Code)


(619) 832-2900

(Registrant’s telephone number, including area code) Telephone Number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Not Applicable Not Applicable Not Applicable


Securities registered pursuant to Section 12(g) of the Act:


Title of each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock ($0.001 par value) ODYY OTC



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.








Item 7.01Regulation FD Disclosure


Attached is a copy of a press release being issued by the Company relating to the above-referenced matter, a copy of which is attached as Exhibit 99.6 and is hereby incorporated.



Item 8.01Other Material Event


On August 4, 2021, Odyssey Group International, Inc. (the “Company”) announced the successful completion of their Investigational New Drug (“IND”) enabling studies and submission of their Investigator’s Brochure (“IB”) for Ethics Committee review to begin Phase 1 clinical trials for the first in-human treatment of concussion. The IB includes the pre-clinical safety and efficacy data, the design for Phase 1 clinical trials and the informed consent to enroll subjects in the trial. The Ethics Committee is expected to complete their review this month.



Item 9.01.Financial Statements and Exhibits.


(d) Exhibits.


Number Exhibit
99.1 Press Release






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: August 6, 2021 Odyssey Group International, Inc.
  By: /s/J. Michael Redmond
  Chief Executive Officer